Coherus BioSciences (CHRS) Misses Q3 EPS by 1c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025 4:14 PM ESTCHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer
Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million
LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025
Conference call today at 5:00 p.m. Eastern Standard Time
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights.
In Q3 2025, we gained... More
